Les flavivirus et leurs vaccins

Virologie

Volumn 2 AUG SUPPL., Issue , 1998, Pages 51-61

  Deubel, V ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Encephalitis; Flavivirus; Haemorrhage; Immune response; Pathogenesis; Recombinant vaccine; Vaccine

Indexed keywords

ARTHROPOD BORNE VIRUS; ARTHROPODA; FLAVIVIRUS; JAPANESE ENCEPHALITIS VIRUS;

EID: 0010705796     PISSN: 12678694     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Deubel V, Flamand M, Marianneau P, Desprès P. Les flavivirus responsables de fièvres hémorragiques. Bull Inst Pasteur/actualités 1997 ; 8 : 195-205.
2. Knudsen AB. Global strategy for the prevention and control of dengue and dengue haemorrhagic fever. In : Saluzzo JF and Dodet B, ed. Emerging diseases : factors in the emergence of arbovirus diseases. Elsevier, « Les Pensières », Annecy, France, 1997 ; 129-40.
3. Robertson SE, Hull BP, Tomori O, Bele O, LeDuc JW, Esteves K. Yellow fever. A decade of reemergence. JAMA 1996 ; 276 : 1157-62.
4. Tsai T. Factors in the changing epidemiology of Japanese encephalitis and West Nile fever. In : Saluzzo JF and Dodet B, ed. Emerging diseases : factors in the emergence of arbovirus diseases. Elsevier, « Les Pensières », Annecy, France. 1997 ; 179-89.
5. Monath TP. Yellow fever and dengue - the interactions of virus, vector and host in the re-emergence of epidemic disease. Semin Virol 1994 ; 5 : 133-45.
6. Monath TP, Heinz FX. Flavivaruses. In : Fields BN, Knipe DM, Howley PM, ed. Fields virology. Lippincott-Raven Press Publishers, Philadelphia, 1996 ; 961-1034
7. Chambers TJ, Hahn CS, Galler R, Rice CM. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 1990 ; 44 : 649-88.
8. Rey F, Heinz FX, Mandl C, Kunz C, Harrison SC. The envelope glycoprotein from tick-borne encephalitis virus at 2A resolution. Nature 1995 ; 375 : 291-8.
9. Mackenzie JM, Jones MK, Young PR. Immunolocalization of the dengue virus nonstructural glycoproiein NS1 suggests a role in viral RNA replication. Virology 1996 ; 220 : 232-40.
10. Rice CM. Flaviviridœ : the viruses and their replication. In Fields BN, Knipe DM, Howley PM, ed. Fields virology. Lippincott-Raven Press Publishers, Philadelphia. 1996 ; 931-59.
11. Hober D, Roulin G, Deubel V, Wattre P. La dengue : une maladie en pleine expansion. Méd Mal Infect 1995 ; 25 : 888-95.
12. Innis BL. Dengue and dengue haemorrhagic fever. In : Porterfield JS, ed. Exotic viral infections. Chapman & Hall, London, 1995 ; 103-46
13. Halstead SB. Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. Rev Infect Dis 1989; 11 : S830-9.
14. Innis BL. Japanese encephalitis virus. In : Porterfield JS, ed. Exotic viral infections. Chapman & Hall Medical, London, UK, 1995 ; 147-74.
15. Gaidamovich SY, Tick-borne flavivirus infections In Proterfield JS, ed. Exotic viral infections. Chapman & Hall Medical, London, 1995 ; 203-17.
16. Marianneau P, Flamand M, Courageot MP, Deubel V, Desprès P. La mort cellulaire par apoptose en réponse à l'infection par le virus de la dengue : quelles conséquences dans la pathogénie virale? Ann Biol Clin 1998 (sous, presse).
17. Chastel C. Réflexions sur deux viroses d'actualité : la fièvre jaune et la dengue. Ann Biol Clin 1997 ; 55 : 415-24.
18. Lee E, Weir R, Dalgarno L. Changes in the dengue virus major envelope protein on passaging and their localization on the three-dimensional structure of the protein. Virology 1997 ; 281 : 281-90.
19. Kawano H, Rostapshov V, Rosen L, Lai CJ Genetic determinants of dengue type 4 virus neurovirulence for mice. J Virol 1993 ; 67 : 6567-75.
20. Desprès P, Frenkiel MP, Deubel V Differences between cell membrane fusion activities of two dengue type-1 isolates reflect modifications of viral structure. Virology 1993 ; 196 : 209-19.
21. Hahn CS, Dalrymple JH, Strauss JH, Rice CM. Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it Proc Natl Acad Sci USA 1987 ; 84 : 2019-23.
22. Aihara S, Chunming R, Yong-Xin Y, Lee T, Watanabe K, Komiya T, et al. Identification of mutations that occurred on the genome of Japanese encephalitis virus during the attenuation process. Virus genes 1991 ; 5 : 95-109.
23. Kinney R, Butrapet S, Chang G-J, Tsuchiya KR, Roehrig J, Bhamarapravati N, et al. Construction of infectious cDNA clones for dengue 2 virus, strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 1997 ; 230 : 300-8.
24. Groshel D, Koprowski H. Development of a virus-resistant inbred mouse strain for the study of innate resistance to arbo B viruses. Arch Gesamte Virusforsch 1965 ; 18 : 379-91.
25. Venugopal K, Gould EA. Towards a new generation of flavivirus vaccines. Vaccine 1994 ; 12 : 966-75.
26. + T-cell response to dengue virus. J Virol 1996 ; 70 : 6540-6.
27. Kurane I, Ennis FE. Immunity and immunopathology in dengue virus infections. Semin Immunol 1992 ; 4 : 121-7.
28. + cytotoxic T-cell clones : multiple patterns of virus cross-reactivity recognized by NS3-specific T-cells clones. J Virol 1991 ; 65 : 1823-8.
29. + human cytotoxic T lymphocytes clones of heterogeneous serotype specificities. J Exp Med 1995 ; 182 : 853-63.
30. Barrett ADT. Yellow fever vaccines. Bull Inst Pasteur 1987 ; 85 : 103-24.
31. Stephenson JR. Flavivirus vaccines. Vaccine 1988 ; 6 : 471-80.
32. Bhamarapravati N, Yoksan S. Live attenuated tetravalent dengue vaccine. In : Gubler DJ and Kuno G, ed Dengue and dengue hemorrhagic fever. CAB International, Oxon-New York, 1997 : 367-77.
33. Liu ZL, Hennessy S, Strom BL, Tsai TE Wan CM, Tang SC, et al. Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2) : results of a randomized trial with 26.239 subjects. J Infect Dis 1997 ; 176 : 1366-9.
34. Chambers TJ, Tsai TF, Pervikov Y, Monath TP. Vaccine development against dengue and Japanese encephalitis : report of a World Health Organization meeting. Vaccine 1997 ; 15 : 1494-502.
35. Chen W, Kawano H, Men R, Clark D, Lai CJ. Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulenee for mice. J Virol 1995 ; 69 : 5186-90
36. Muylaert IR, Chambers TJ, Galler RG, Rice CM. Mutagenesis of the N-linked glycosylation sites of the yellow fever virus NS1 protein : effects on virus replication and mouse neurovirulence. Virology 1996 ; 168 : 159-68.
37. Sumiyoshi H, Tignor GH, Shope RE. Characterization of a highly attenuated Japanese encephalitis virus generated from molecularly cloned cDNA. J Infect Dis 1995 ; 171 : 1144-51.
38. Cahour A, Pletnev A, Vazeille-Falcoz M, Rose L, Lai CJ. Growth-restricted dengue virus mutants containing deletions in the 5′ non-coding region of the RNA genome. Virology 1995 ; 207 : 68-76.
39. Men R, Bray M, Clark D, Chanock RM, Lai CJ. Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome : analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Virol 1996 ; 70 : 3930-7.
40. Bray M, Men R, Lai C. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge. J Virol 1996 ; 70 : 4162-6.
41. + cytotoxic T lymphocytes in mice. Virology 1997 ; 227 : 353-60.
42. Pugachev K, Mason P, Frey T. Sindbis vectors suppress secretion of subviral particles of Japanese encephalitis virus from mammalian cells infected with SIN-JEV recombinants. Virology 1995 ; 209 : 155-66.
43. Konishi E, Win KS, Kurane I, Mason PW, Shope RE, Ennis FA. Particulate vaccine candidate for Japanese encephalitis induces long-lasting virus-specific memory T lymphocytes in mice. Vaccine 1997 ; 15 : 281-6.
44. Jan L-R, Yang C-S, Henchal LS, Sumiyoshi H, Summers PL, Dubois DR, et al. Increased immunogenicity and protective efficacy in outbred and inbred mice by strategic carboxy-terminal truncation of Japanese encephalitis virus envelope glycoprotein. Am J Trop Med Hyg 1993 ; 48 : 412-23.
45. Men R, Bray M, Lai C-J. Carboxy-terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extra-cellularly exhibit increased immunogenicity in mice. J Virol 1991 ; 65 : 1400-7.
46. Heinz FX, Allison SL, Stiasny K, Schalich J, Holzmann H, Mandl CW, et al. Recombinant and virion-derived soluble and particulate immunogens for vaccination against tick-borne encephalitis. Vaccine 1995 ; 13 : 1636-42.
47. Flamand M, Desprès P, Delenda C, Deubel V. La stratégie du baculovirus au service des virus de la dengue, de l'encéphalite japonaise et de la fièvre jaune : les futurs vaccins de seconde génération ? Ann Inst Pasteur/Actuaiités 1992 ; 3 : 166-78.
48. Staropoli I, Frenkiel MP, Mégret F, Deubel V. Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity. Vaccine 1997 ; 15 : 1946-54.
49. Robinson HL Nucleic acid vaccines : an overview. Vaccine 1997 ; 15 : 785-7.
50. Phillpotts RJ, Venugopal K, Brooks T. Immunisation with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus. Arch Virol 1996 ; 141 : 743-9.
51. Schmaljohn C, Vanderzanden L, Bray M, Custer D, Meyer B, Li D, et al. Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and central European encephalitis virus protect mice from homologous and heterologous challenge. J Virol 1997 ; 71 : 9563-9.
52. Kochel T, Wu S, Raviprakash K, Hobart P, Hoffman S, Porter K, et al. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice Vaccine 1997 ; 15 : 547-52.
53. Lin YL, Chen LK, Liao CL, Yeh CT, Ma SH, Chen JL, et al. DNA immunization with Japanese encephalitis virus nonstructural protein NS1 elicits protective immunity in mice. J Virol 1998 ; 72 : 191-200.